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Abstract
To better understand the nature of B cell dysfunctions in subjects infected with HIV-1 subtype A, a rural cohort of 50
treatment-naı ¨ve Ugandan patients chronically infected with HIV-1 subtype A was studied, and the relationship between B
cell depletion and HIV disease was assessed. B cell absolute counts were found to be significantly lower in HIV-1+ patients,
when compared to community matched negative controls (p,0.0001). HIV-1-infected patients displayed variable functional
and binding antibody titers that showed no correlation with viral load or CD4+ T cell count. However, B cell absolute counts
were found to correlate inversely with neutralizing antibody (NAb) titers against subtype A (p=0.05) and subtype
CRF02_AG (p=0.02) viruses. A positive correlation was observed between subtype A gp120 binding antibody titers and
NAb breadth (p=0.02) and mean titer against the 10 viruses (p=0.0002). In addition, HIV-1 subtype A sera showed
preferential neutralization of the 5 subtype A or CRF02_AG pseudoviruses, as compared with 5 pseudoviruses from
subtypes B, C or D (p,0.001). These data demonstrate that in patients with chronic HIV-1 subtype A infection, significant B
cell depletion can be observed, the degree of which does not appear to be associated with a decrease in functional
antibodies. These findings also highlight the potential importance of subtype in the specificity of cross-clade neutralization
in HIV-1 infection.
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Introduction
Human immunodeficiency virus (HIV) infection leads to
dysregulation of the host immune system resulting in acquired
immunodeficiency syndrome (AIDS), opportunistic infections,
malignancies and eventual death. In the majority of untreated
cases, infection with HIV-1 ultimately results in elevated viral
replication leading to depletion and impairment of CD4+ T cells
[1,2] one of the primary markers used for monitoring patients and
characterizing disease progression. Chronic HIV-1 infection also
leads to B cell dysfunction through mechanisms that are poorly
understood [3,4]. While an intact memory B cell compartment is
required to guard against future infections [5], in HIV-1 chronic
infection, circulating memory B cells have been observed to be
markedly reduced, potentially as a result of increased apoptosis
[6,7]. HIV-1 induces numerous B cell abnormalities, including
hypergammaglobulinemia and B cell hyperactivation [8,9,10] B
cell exhaustion [11], increased expression of activation markers
[12], spontaneous secretion of antibodies in culture [13], and a
higher incidence of B-cell lymphomas [14]. Persons with chronic
HIV-1 infection also show impaired humoral responses to
vaccination and their B cells respond poorly to in vitro stimulation
[15]. Importantly, the early initiation of anti-retroviral therapy
soon after HIV infection has recently been shown to preserve the
memory B cell compartment and minimize damage to B cell
responses in HIV infection [16]. Memory B cells are vital for the
maintenance of antibody levels and rapidly initiate secondary
immune responses upon re-infection or antigenic stimulation [17].
Antigen-induced B cell proliferation and differentiation is
dependent on direct cross-talk with CD4+ T cells, however
soluble gp120 can interfere with this interaction [18]. If this
interaction is disrupted, germinal center reactions are inhibited,
the microenvironment for somatic hypermutation will not be
established and thus, B cell differentiation may be aborted. In
HIV-1 infection, elevated viral plasma load and disease progres-
sion have also been shown to be associated with loss of B cell
reactivity [19].
More than 33 million people are infected with HIV-1
worldwide and a preventive vaccine is urgently needed. It has
been proposed that an efficacious HIV vaccine will require
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e22653effective T cell immunity, as well as cross-reactive, functional
antibodies. Neutralizing antibody (NAb) responses to HIV-1 are
therefore a high priority for HIV-1 vaccine development [20,21].
Cross- subtype NAbs have been found in the sera of HIV-1
infected individuals and numerous studies have reported prefer-
ential recognition and inhibition of preceding autologous viral
strains, implying that HIV-1 quickly escapes selective antibody
pressure [22,23,24,25]. Nevertheless, some patients do demon-
strate potent, broadly cross-reactive neutralization by targeting
epitopes of the HIV-1 envelope protein. The relationship between
these responses and disease progression in subjects infected with
HIV-1 subtypes other than B has been characterized in a limited
number of studies [26,27,28].
Another functional HIV-1 antibody response, antibody-depen-
dent cell-mediated cytotoxicity (ADCC), has been correlated with
viral load and rate of progression to AIDS [29,30,31,32,33].
Despite substantial research to reveal the presence and magnitude
of ADCC at different stages of HIV-1 disease [29,30,34,35] and
the potential protective effect of this response in vaccinated animal
models [36,37,38], the relevance of ADCC in HIV-1 infection is
still unclear. HIV-1 specific immune responses such as ADCC and
cytotoxic CD8+ T-cells are likely to lead to destruction of HIV-1-
infected CD4+ T cells resulting in gradual loss of T cell ‘‘help’’ to
B cells, thereby contributing to a reduction in B cell numbers and
dysfunctions in antibody secretion. In contrast to HIV-1-specific
NAbs that are known to deter free virus by blocking receptor
engagement, interfering with the fusion process, or by other
mechanisms [39], the roles of many other binding antibodies
elicited in natural infection are poorly understood. Additional
functional consequences of binding antibodies may include
pathogen opsonisation, inhibition of bystander cell apoptosis, or
enhancement of infection.
Given the limited number of studies performed to explore B
cells, antibody function and markers of disease progression in non-
B subtype infections, we have characterized the peripheral blood B
cell absolute counts and serum antibody functions in untreated
HIV-1 subtype A infected Ugandan patients. These subjects were
enrolled in a vaccine cohort development protocol in Kayunga
district in rural Uganda where the HIV-1 prevalence was 9.9%
and the subtype distribution was found to be 45% subtype A, 23%
D, 1% C, 23% recombinants and 8% represented dually reactive
subjects [40]. Here we show the impact of HIV-1 subtype A-
associated B cell depletion on overall binding antibodies, NAb
responses and ADCC activity. We demonstrate for the first time
an inverse correlation between B cell number and NAb titers
against a panel of ten acute pseudoviruses from five different
subtypes. Additionally, the NAbs from subtype A-infected subjects
demonstrate subtype preference with more frequent responses and
a higher geometric mean titer against subtype A-containing
pseudoviruses. These findings may provide important information
for vaccine development in East Africa, where HIV-1 subtypes A,
C and D are the most prevalent [41].
Materials and Methods
Subjects
Study participants were recruited from a cohort established for
possible HIV-1 vaccine trials, as previously reported [40]. Samples
were obtained from 192 HIV-1 infected, treatment naı ¨ve subjects
and 262 HIV-seronegative individuals; 50 subtype A HIV-1
infected subjects were randomly selected for study in antibody
assays. This study was approved by institutional review boards in
the US, Division of Human Subjects Protection at the Walter
Reed Army Institute of Research and the institutional Review
Boards of Uganda’s National Council for Science and Technology
(UNCST) and the National AIDS Research Committee (NARC).
Study participants were aged 15–49 years and provided written
informed consent before blood draw. Written assent was obtained
from the parent or legal guardian of those participants aged 15–
17.
HIV-1 testing, viral load determination, and
immunophenotyping
Sera were screened for HIV-1 by ELISA using the Genetic
Systems rLAV ELISA (BioRad Laboratories, Redmond, WA),
followed by testing of reactive samples in duplicate using the
Vironostika HIV-1 Microelisa Systems (Organon Teknika,
Durham, NC). Samples repeatedly reactive were confirmed by
Genetic Systems HIV-1 Western Blot (BioRad Laboratories,
Redmond, WA). Viral burden was measured on plasma using the
HIV-1 Monitor Test version 1.5 (Roche Diagnostics, Indianapolis,
IN). Virus subtype analysis was performed on plasma using the
multi-region hybridization (MHA) assay for subtypes A, C, and D
that was designed to identify HIV-1 subtypes, recombinants, and
dual infections in a rapid, high throughput, real-time PCR
(Applied Biosystems 7900HT Fast Real-Time PCR, Applied
Biosystems, Carlsbad, CA) [42,43]. Enumeration of lymphocyte
subsets was performed using FACS MultiTEST System that
utilizes Multi-test 4-color reagents and TruCount tubes in a single
platform flow cytometry based system (Becton Dickson (BD), San
Jose, CA). Samples were aquired and analyzed on a dual laser BD
FACSCalibur. B cell subsets were defined using the anti-human
CD19, clone SJ25C1 conjugated to allophycocyanin (APC).
TZM-bl cells
TZM-bl cells were obtained from NIH AIDS Reagent program,
as contributed by John Kappes and Xiaoyun Wu. TZM-bl are
genetically engineered cells, derived from a HeLa cell line. They
express CD4, CXCR4 as well as CCR5 and contain Tat-
responsive reporter genes for firefly luciferase and Escherichia coli b-
galactosidase under regulatory control of an HIV-1 long terminal
repeat (LTR) [44,45]. The cells were maintained in Dulbecco’s
modified Eagle’s medium (Invitrogen, Carlsbad, CA) containing
10% heat-inactivated fetal bovine serum and gentamicin (50 mg/
ml). Cells were incubated at 37uC with 5% CO2. Cell monolayers
were split 1:10 at confluence by treatment with 0.25% trypsin,
1 mM EDTA (Invitrogen).
Pseudoviruses
Molecularly cloned gp160 genes representing standard panels of
HIV-1 reference strains for subtypes A (92RW020.2, Q842.d12,
Q23.17), B (WITO4160.33, QH0692.42), C (Du172.17, CAP45.
2.00.G3), D (A08483M1.vrc9a), and CRF02_AG (PT271.11,
PT250.4), from newly transmitted, sexually acquired infections
were used in the neutralization assays. All env-pseudotyped viruses
were prepared by co-transfection with an env-defective backbone
plasmid (pSG3Denv) in 293T cells and titrated in TZM-bl cells.
Neutralizing antibody assay
Neutralizing antibodies were measured as a function of
reduction in luciferase reporter gene expression after a single
round of infection in TZM-bl cells, as described [46]. Briefly, virus
was pretitered to determine the dilution of pseudovirus sufficient to
produce 150,000 relative light units (RLU) from luciferase
expression at day 2 post-infection. This dilution of virus then
was incubated with serial 3-fold dilutions of heat-inactivated sera
in duplicate in a total volume of 150 ml for 1 hr at 37uC in 96-well
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100 ml of growth media containing 25 mg/ml DEAE dextran) were
added to each well. One set of control wells received cells plus
pseudovirus (virus control) and another set received cells only
(background control). After a 48 hr incubation, 150 ml of culture
medium was removed from each well and 100 ml of Britelite
reagent (PerkinElmer, Waltham, MA) was added to the cells. After
a 2-minute incubation at room temperature to allow cell lysis,
150 ml of cell lysate was transferred to CostarH 96-well black solid
plates (Corning, Lowell, MA) for measurements of luminescence
using a Victor2
TM luminometer (Perkin Elmer). The 50%
inhibitory dose (ID50) was defined as the serum dilution that
caused a 50% reduction in RLU compared to virus control wells,
after subtraction of background RLU.
Binding antibody assay
IgG antibody titers were measured in plasma using recombinant
envelope glycoprotein subtype A gp120 (Aalto Bio Reagents Ltd.,
Dublin, Ireland). 96-Well ELISA plates were coated overnight at
4uC with 100 ml PBS/Well containing anti-gp120 antibody. Plates
were washed three times with PBS/0.05% Tween-20 wash buffer.
Half the plate was then coated with gp120 antigen (0.5 mg/ml) in
distilled water and incubated at 37uC for 1 hr. Plates were washed
three times with wash buffer and blocked with diluent containing
5% dry milk for 1 hr at 37uC. Samples were serially diluted and
added to the ELISA plate (100 ml/well) for 1 hr at 37uC. After
washing five times, a secondary peroxidase-labeled goat anti-
human IgG (H+L) (KPL, Gaithersburg, MD), diluted 1:5000 in
wash buffer was added (100 ml/well). Plates were incubated for
1h r a t 3 7 uC, washed three times and developed with TMB
substrate (KPL) for 20 minutes at room temperature. The plates
were analysed at 405 nm with an ELX 800 universal microplate
reader (Bio-Tek Instruments, Winooski, VT). After subtraction of
the background, endpoint titers for each sample were established
as the last dilution with a corrected optical density of greater than
0.1.
ADCC assay
The ADCC assay was performed as described previously [47].
Briefly, 2610
6 CEM.NK
r cells were labelled with 200 mCi
radioisotope Na
51CrO4 (
51Cr) for 1 hr at 37uC. Following washing
to remove excess chromium, the cells were incubated with HIV-1
recombinant gp120 subtype B protein (Protein Sciences Corp,
Meridian, CT) at 1 mg (10 ml) per 1610
6 cells in a total volume of
300 ml and unbound gp120 was washed out. Target cells were
plated at 50 ml per well from a target stock of 5610
4 cells/ml and
incubated for 20 minutes at room temperature (20 to 30uC) with
50 ml of 10-fold serial dilutions (10
2 to 10
6) of heat inactivated
participant sera. A serum sample with demonstrable ADCC
activity was used as positive control and also to normalize the
assay. Peripheral blood mononuclear cells (PBMC) derived from a
single HIV-1 seronegative Thai donor were used as effector cells.
On the day before the assay, cryopreserved PBMC were thawed
and incubated overnight and added to the targets at an effector-to-
target ratio of 100:1. The effectors, serum, and target cells were
incubated together for 6 hrs. Either sodium dodecyl sulfate (SDS)
or cell culture media was added to target cells to measure maximal
or spontaneous release, respectively. Chromium release was
measured by using a Top-Count NXT
TM (Packard Bioscience
Company, Meridian, CT, USA). Percentage specific lysis was
calculated as 100 [(mean test cpm – mean spon cpm)/(mean max
cpm – mean spon cpm)], where test cpm=counts per minute
released by the CEM.NK
r target cells in the presence of effector
cells, spon cpm=cpm released by the CEM.NK
r target cells in the
absence of any effector cells, and max cpm – cpm released by the
target cells in the presence of SDS. In order to normalize results, a
positive control was run on every plate on each day the assay was
performed and the positive control mean maximum lysis was
calculated. Maximum lysis for each sample was calculated as a
ratio to the mean maximum lysis of the positive control run on the
same day.
Statistical analyses
Statistics were performed using Prism (GraphPad Software Inc.,
San Diego, CA) statistical analysis software. Comparisons of
groups were performed using the Mann-Whitney test. Correlation
was analyzed using the non-parametric two-tailed Spearman’s
rank test. P values less than 0.05 were considered statistically
significant.
Results
Absolute B cell counts are significantly lower in HIV-1
subtype A-infected Ugandans, as compared to HIV-1
negative controls
The whole blood absolute counts and percentages of T and B
cells were measured in 192 treatment-naive patient samples and
261 samples from HIV-1 negative, community matched control
subjects. Fifty HIV-1 subtype A infected patients were selected for
further humoral analyses. The median B cell absolute count in
HIV-1 uninfected subjects was 333 cells/ml with a range of 83–
1160 cells/ml, while the median absolute B cell count in subtype A
infected patients was 190 cells/ml, with a range of 20–572 cells/ml.
Compared to their HIV-1 negative counterparts, all HIV-1
infected subjects and the subset of 50 HIV-1 subtype A infected
subjects, when analyzed as separate groups, both showed a
significant reduction in absolute B cell numbers (p,0.0001, Fig. 1).
B cell depletion in HIV-1 subtype A infection is
accompanied by a reduction in T-Helper cell number and
an increase in viral load
To investigate if the observed B cell depletion was related to
lower numbers of CD4+ T cells or higher viral loads, the absolute
counts of T-helper cells were compared with B cell counts and
viral load. As shown in Fig. 2A, the absolute number of B cells
correlated directly with the CD4+ T cell count, a primary marker
of disease progression in HIV-1 infection (Spearman, p=0.002,
rho=0.43). The median CD4+ T cell count was 448 cells/ml with
a range of 3–1350 cells/ml. The mean viral load (copies of HIV-1
RNA/ml) was 48,989, with a range of 2,702–750,000 copies per
ml. Viral load showed an inverse relationship with CD4+ T cells,
using both absolute counts (Spearman, p=0.06, rho=20.37,
Fig. 2B) and percentage (Spearman, p=0.009, rho=20.26,
Fig. 2C). There was no correlation between viral load and
absolute B cell counts (Spearman, p=0.68, r=20.06, data not
shown).
B cell numbers in HIV-1 subtype A infected individuals
correlate inversely with neutralization titers against
different HIV-1 subtypes in the TZM-bl pseudovirus assay
To assess the relationship between B cell numbers and
functional antibodies, neutralization breadth and potency was
assessed using sera from the 50 HIV-1 subtype A infected patients.
The TZM-bl neutralization assay was employed using a panel of
10 acute pseudoviruses from 5 different subtypes (see Materials
and Methods). The mean 50% neutralizing titers (ID50) were
calculated for each serum against the pseudoviruses grouped by
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pseudoviruses together. Individual results with an ID50#10 were
considered negative and assigned a value of 10, whereas for sera
having an ID50.10, the actual titer values were included in the
analyses. The patients’ B cell counts showed a significant negative
correlation with the mean ID50s against the 10 pseudoviruses
(Spearman, p=0.04, rho=20.36, Fig. 3A). This was also true for
the grouped CRF02_AG pseudoviruses (Spearman, p=0.02,
rho=20.35, Fig. 3B), and a similar trend was observed for
subtype A pseudoviruses (Spearman, p=0.05, rho=20.31,
Fig. 3C), and for subtype C viruses (p=0.03, data not shown). A
trend was also seen when comparing the B cell absolute counts
with the neutralization titers against each of the individual subtype
A pseudoviruses, 92RW020.2 and Q842.d12 (Spearman, p=0.06,
p=0.07, respectively); no additional correlations were observed
for the other subtypes or individual viruses (data not shown). The
mean ID50 values for each of the 50 sera against the 10 different
pseudoviruses ranged from 23 to 11,270, with a median of 112. As
can be seen in Fig. 3D, there is also a trend towards an inverse
correlation (Spearman, p=0.08) between B cell numbers and the
breadth of neutralizing antibody responses (as measured by the
total number of panel pseudoviruses neutralized).
Sera from patients infected with HIV-1 subtype A
preferentially neutralize subtype A and the recombinant
CRF02_AG
To analyze the subtype-specific frequency, breadth and potency
of neutralization, the ID50 values were tabulated for all 50 subtype
A sera against each of the 10 pseudoviruses within the five
subtypes, as shown in Fig. 4. Values .10 were highlighted in red
boxes, and the sera were ranked from those with highest breadth
(top) to those with the lowest (bottom). The breadth of
neutralization for each of the different sera ranged from 10% to
100%. Five out of 50 (10%) serum samples could neutralize all ten
pseudoviruses (100% breadth), eight sera neutralized nine out of
ten pseudoviruses (90% breadth), and only one serum (sample
#47) showed a very low breadth of 10% (Fig. 4). For each viral
subtype, the number of positive neutralization titers was scored,
and the percent of positive neutralization titers was calculated and
graphed by subtype, as shown in Fig. 5 (black bars, left Y-axis).
These 50 HIV-1 subtype A sera showed the most frequent overall
neutralization of the 2 subtype CRF02_AG viruses (total of 85%
positives), followed by a frequency of 72% against the 3 combined
subtype A viruses. Positive response rates against subtypes B, C,
and D were 57%, 42% and 22%, respectively. The data set for
subtype D was small with only 50 values against one subtype D
virus. We therefore assessed whether the frequency of subtype A
serum neutralization of subtype A and CRF02_AG viruses was
greater than that observed against non-A viruses, as might be
expected if subtype plays a role in neutralization [48,49].
Grouping together the five A and CRF02_AG viruses and
grouping the five non-A (B, C, and D) viruses together, the
number of positives within the 250 tests (50 sera65 viruses) in each
subtype grouping was scored. The differences between subtype A
serum neutralization of A and CRF02_AG viruses (77% positive)
versus neutralization of non-A (B, C, D) viruses (44% positive) was
highly significant (p,0.001, Fisher’s exact test). In addition, the
geometric mean ID50 values for all 50 subtype A sera against the
1–3 viruses within each subtype were calculated. The 50 subtype A
sera showed the greatest overall potency (about 2-fold higher
geometric means) against subtypes A and CRF02_AG (Fig. 5,
white bars). The error bars represent the 95% confidence intervals.
Overall, the potencies of subtype A serum NAb responses were
ranked in the following order: CRF02_AG.A.D.C.B, with
corresponding geometric mean ID50s of 243.238.126.106
.98, respectively, (Fig. 5, right hand Y-axis, white bars). These
observations require further analyses as the numbers of viruses
were small (5 each of A versus non-A pseudoviruses) and there was
only one subtype D virus in the panel.
Correlation between gp120 binding antibody titers and
NAb titer and breadth in sera from HIV-1 subtype A
infected Ugandans
IgG binding antibodies against HIV-1 subtype A gp120 were
measured by ELISA using the 50 sera from HIV-1 subtype A
infected Ugandans. The titers ranged from 25,600 to 24,000,000
with a mean of 714,971. Interestingly, a significant correlation was
observed between gp120 IgG binding titer and mean NAb titer
against all ten pseudoviruses (Spearman, p=0.0002, rho=0.54,
Fig. 6A). A significant correlation was also found between gp120
binding and mean NAb titer against viruses from subtypes A
(Spearman, p=0.01, rho=0.41) and CRF02_AG (Spearman,
p=0.001, rho=0.5, Fig. 6C and B, respectively). In addition, a
significant correlation could be seen between gp120 binding titer
and the ID50 against pseudoviruses from HIV-1 subtype C
(p,0.03) and against the individual pseudoviruses 92RW020.2
(subtype A), Du172.17 (subtype C) and PT271.11 (subtype
CRF02_AG), all with p,0.03. The gp120-binding antibody titers
also correlated with the breadth of neutralization, as measured by
the number of viruses neutralized (out of 10) (Spearman, p=0.02,
rho=0.36, Fig. 6D). Of note, gp120 binding antibody titers did
not correlate with absolute B cell counts, CD4 counts or viral load
(data not shown).
Figure 1. The absolute B lymphocyte count in HIV-1 subtype A
infected patients is significantly lower than in HIV-1 negative
controls. Samples of whole blood from HIV-1 infected and uninfected
individuals were analysed using flow cytometry and the MultiTEST
TM
IMK Kit (BD). Lymphocyte subpopulations were quantified and samples
from 261 HIV-1 negative individuals (white box) were compared with
HIV positives. The absolute counts of CD19+ B lymphocytes in 50 HIV-1
subtype A infected patients (grey box) and in 192 patients with all HIV-1
subtypes combined (hatched box) were significantly reduced in
comparison to uninfected participants. (p,0.0001, Mann-Whitney test).
The whiskers represent the range from the 10th–90th percentile.
doi:10.1371/journal.pone.0022653.g001
B Cell Depletion in HIV-1 Subtype A Infection
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e22653ADCC in sera from subtype A infected Ugandans
In optimizing the ADCC assay, we found that the subtype A
gp120 available for use in the ELISA assays provided no positive
responses, presumably due to poor binding to the CEM.NK
r
target cells. Thus, the ADCC assay was established using the
subtype B gp120 used in previous studies by our laboratories
[47,50]. To establish a negative cut-off for the ADCC assay,
ADCC activity was measured for the HIV-1 positive control sera
and compared with activity in the negative controls. The mean %
specific lysis for HIV+ controls was 37.7% (range 27.7–49.7%), as
compared to 5.6% (range 3.1–8.3%) for the negative controls.
Based on this, the mean ratio of the negative control after
normalization was 0.15. Considering experimental error, we
defined a negative response as one with a ratio of ,0.2 and
positives as a ratio of $0.2. Overall, 46/50 samples had
demonstrable ADCC activity against targets coated with subtype
B gp120. The mean ratio for ADCC specific lysis for samples that
showed ADCC responses was 0.67 as compared to a ratio of 0.1
for the ADCC negative samples. However, ADCC responses did
not correlate with absolute B cell counts (Spearman, p=0.26), B
cell percentage (Spearman, p=0.12), absolute CD4+ T cell
Counts (Spearman, p=0.78) or viral load (Spearman, p=0.16).
In addition there was no relationship observed between ADCC
and mean NAb titer (Spearman, p=0.19) or gp120 binding
antibodies (Spearman, p=0.64) (data not shown).
Discussion
Here we report significant peripheral blood B lymphopenia in
HIV-1 subtype A infected Ugandans (Fig. 1), supporting several
studies that have demonstrated B cell deficiencies and dysfunction
in chronic HIV-1 infection [6,7,51,52,53,54,55,56,57,58,59,60].
In addition, the profiles of gp120 binding and functional
antibodies were assessed in sera from this cohort of Ugandan
patients. Comparisons were made between B cell counts, viral load
and CD4 numbers (Fig. 2) in order to determine the impact of the
reduced peripheral B cell numbers on antibody functions and on
disease stage in HIV-1 subtype A infection. High titers of NAbs
[25] and potent ADCC-specific responses [33] have been
demonstrated in chronic HIV infection, and a number of studies
have investigated the prognostic role of these antibodies
[23,25,29,31,32,34,35,36]. The inverse correlation observed
between CD4+ T cell count and viral load supports the expected
relationship between these markers and is consistent with previous
studies that demonstrate CD4 T cell decline as the hallmark of
progressive HIV infection [1,2]. Our findings suggest that this
rural Ugandan population with chronic untreated subtype A HIV-
1 is similar to other HIV-infected populations, where CD4+ T cell
decline, increased viral load and subsequent immune dysfunction
have been observed. The correlation between absolute B cell and
CD4 T cell counts (Fig. 2a) also supports previous findings in
chronically infected individuals [52]. Recently, it has also been
shown that SIV infection in macaques results in a loss of both
naı ¨ve and memory B cells during and after acute stages of infection
[61].
Viral load did not show an inverse relationship with B cell
counts, which might have been expected (Fig. 2). While B cells are
not the target cells for virus replication, the profile of B cell
phenotypes in peripheral blood is perturbed in HIV-1 infection
[4]. Increased viral load results in B cell co-stimulatory dysfunction
Figure 2. Absolute CD4+ T lymphocyte counts correlate with B lymphocyte absolute counts, but not with HIV-1 viral Load. The
absolute counts of B lymphocytes correlated with the absolute number of CD4+ T lymphocytes (A). The number of plasma HIV-1 RNA copies/ml
showed a significant inverse correlation with the CD4+ T lymphocyte percentage (C) and a trend towards correlation with CD4 absolute number (B).
doi:10.1371/journal.pone.0022653.g002
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during primary infection [51]. HIV-1 has been shown to be
capable of attaching to B cells via interactions between the CR2
complement receptor (CD21) and complement proteins bound to
the virus. This interaction may provide stimulatory signals to B
cells and, more importantly, may facilitate the transmission of
HIV-1 to CD4+ T cells [4]. It has also recently been proposed that
CD40L-bearing HIV-1 particles expressed by productively
infected CD4+ T cells may play a role in the virus-induced
humoral immune dysfunction by chronic activation of B cells
through sustained CD40 signalling [10]. The lack of correlation of
viral load and B cell number suggests that the virus is not
specifically driving B cell depletion, but rather supports a model
where CD4+ T cell decline diminishes the help that B cells
require. It has been demonstrated that high levels of antigenic
stimulation, as well as greater envelope genetic diversity early in
infection, may generate broader NAb breadth, which is accom-
panied by a higher viral load set point [28].
In this study, no correlation was found between anti-gp120
binding antibodies and absolute B cell counts, viral load or CD4+
T cell counts, but there was a strong correlation of subtype A
gp120 binding antibodies with Nab titer and breadth. These
findings are in agreement with results from a longitudinal study
characterizing the evolution of humoral responses in Thai patients
infected with subtype CRF01_AE [26]. The correlation between
neutralizing and binding antibody titers (Fig. 6B) as well as binding
antibody titers and breadth (Fig. 6D) is important in the context of
characterizing factors in HIV-1 pathogenesis and progression that
could be indicators or correlates of protection for vaccine
development. The impact of functional and binding antibody
responses on disease progression has not been fully characterized
in all subtypes. Since high titers of NAbs emerge later during
infection, it is possible that the initial titers of binding antibodies
may predict generation and evolution of NAbs. However, the
kinetics involved in the evolution of subtype A binding and NAbs
cannot be examined in this study, and will require longitudinal
follow-up of subtype A infected patients, as is planned in an
ongoing clinical protocol to assess acute infection in Uganda,
Tanzania, and Kenya.
In assessing a direct relationship between peripheral B cell
numbers and functional antibodies, an intriguing inverse correla-
tion was observed between the mean NAb titer (against ten
pseudoviruses) and the absolute B cell count. The weak inverse
correlation found may be partially explained by the events of B cell
Figure 3. B lymphocyte absolute counts in HIV-1 subtype A infected Ugandans correlate inversely with neutralizing antibody titers
against different HIV-1 subtypes. Neutralizing antibody responses in sera of 50 HIV-1 subtype A infected patients were determined against a
panel of 10 pseudoviruses in the TZM-bl Assay. The mean ID50 using each serum sample against all 10 pseudoviruses or against all pseudoviruses
within a subtype was calculated. B lymphocyte numbers showed a significant inverse correlation with neutralizing antibody titers against the mean
ID50 of all 10 pseudoviruses (A) and with the mean ID50 for subtype CRF02_AG (B); the same trend was observed for subtype A viruses (C). B
lymphocyte numbers also showed a trend towards inverse correlation with breadth (number of panel viruses neutralized) (D).
doi:10.1371/journal.pone.0022653.g003
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exposure to sufficient doses of viral antigen(s). In response to
ligation of their cell-surface immunoglobulin, naı ¨ve B cells
undergo clonal expansion and differentiation, developing either
into memory cells or antibody secreting cells (ASC). IgG ASCs
mainly traffic to the bone marrow or inflammatory sites,
irrespective of their site of induction [63]. Thus, while these B
cells are potentially secreting important functional antibodies, they
may be trafficked out of the peripheral blood compartment, thus
leading to decreased numbers of CD19+ B cells identified in
peripheral blood, in the setting of antibody production against
increasing epitopic exposure. As these B cells exit out of the
peripheral circulation they may also become sequestered in
secondary lymphoid tissue as infection progresses.
Of note, Beniguel et al. have demonstrated the potential for
intact functional humoral responses, despite major B cell
perturbations induced by HIV-1 and other tropical pathogens,
in chronically infected, drug-naı ¨ve African subjects [64]. Thus, it is
likely that functional antibodies against HIV-1 are detected (even
at elevated levels) concomitant with a decline in the numbers of
CD19+ peripheral B cells. Indeed, this is the first demonstration of
an actual inverse relationship between B cells remaining in
peripheral blood and HIV-1 NAb responses against subtype-
matched and heterologous viruses. It is also important to note that
in this study, only CD19+ B cells were enumerated and no
additional phenotypic characterization of specific B cell sub-
populations was performed. Future studies should aim to perform
in depth characterization of the frequencies of specific populations
Figure 4. Breadth of neutralization in HIV-1 subtype A infected patient sera. Shown is the breadth of neutralization for each serum sample
against a panel of 10 pseudoviruses from five different subtypes (Purple columns=subtype CRF02_AG, yellow=subtype A, green=subtype B,
blue=subtype C and orange=subtype D). Red boxes indicate ID50s.10 (positive neutralization). HIV-1 subtype A infected subjects showed more
frequent neutralization against subtypes CRF02_AG and A, as compared to non-A subtypes (p,0.001, Fisher’s exact test).
doi:10.1371/journal.pone.0022653.g004
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role(s) in functional responses.
In this study we demonstrate heterologous responses across
different subtypes, consistent with previously reported findings
[65,66], as well as recent results from our laboratory demonstrat-
ing strong responses against subtype CRF02_AG viruses in
Ugandan sera (Ouma et al., manuscript in preparation). A subset
(approximately 10%, Fig. 4) of the subtype A serum samples in the
present study demonstrated neutralization of all ten viruses
representing five subtypes, and this is in agreement with the
findings of neutralization breadth observed in other studies
[67,68,69]. Blish et al. described the presence of cross-neutralizing
antibodies in Kenyan plasma from subjects infected with subtypes
A, C and D against viruses from multiple subtypes [70]. These
broadly neutralizing antibodies may be a result of the targeting of
conserved epitopes, alternatively, these samples might have been
derived from later in chronic infection, allowing for the
accumulation of a library of neutralizing antibodies representing
the history of epitopes displayed by the infecting virus. This notion
is also supported by findings in longitudinal studies in progression
cohorts [71,72,73], although these studies involved subtype B
infected long-term non-progressors and the use of T cell line-
adapted (TCLA) strains or primary isolates.
Our findings also support some degree of subtype-specificity in
the cross-clade neutralization observed. The subtype A sera
showed significantly more frequent neutralization of, and higher
Figure 5. Patients infected with HIV-1 subtype A show greater
frequency and magnitude of neutralization against subype A
and CRF02_AG viruses. Sera from 50 HIV-1 subtype A-infected
patients were tested in the TZM-bl neutralization assay against 1–3
pseudoviruses of each subtype indicated. The frequency of neutraliza-
tion (% of titers .10) of viruses in a given subtype (black bars), as well
as the geometric mean titer (ID50, white bars) against each viral
subtype, is shown. For the geometric mean titers, the error bars
represent the 95% confidence intervals.
doi:10.1371/journal.pone.0022653.g005
Figure 6. Binding antibodies against HIV-1 gp120 correlate with mean NAb Titer and breadth of neutralization. Subtype A gp120
binding antibody titers correlate with the mean NAb titers against all 10 pseudoviruses (A) and the mean ID50s of subtype CRF02_AG (B) and subtype
A (C) pseudoviruses. A significant correlation was also seen between the gp120 binding antibody titers and neutralization breadth, as measured by
the number of viruses neutralized (D).
doi:10.1371/journal.pone.0022653.g006
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containing envelopes (Figs. 4 and 5). While these data should be
further substantiated with a larger virus panel (ie. only one subtype
D virus was tested), the findings are important and suggestive
regarding the influence of HIV-1 subtype in humoral immune
responses. A growing number of studies have demonstrated that
subtype can play a role in the specificity, frequency and perhaps
magnitude of HIV-1 neutralization [48,49,74]. It has also been
proposed that HIV-1 subtypes may vary in rates of disease
progression [75], and this has been supported by data demon-
strating that subtype D is associated with more rapid progression
to AIDS [76,77]. It will be important to determine the profiles of
neutralizing antibody magnitude and breadth in subjects infected
with subtype A, as this subtype is quite prevalent, particularly in
Africa, and subtype A is a component of the two circulating
recombinant forms (CRF01_AE and CRF02_AG) included
amongst the major subtypes in the pandemic [41].
The failure of ADCC responses to correlate with B cell counts,
viral load, CD4+ T cell counts and functional antibodies is a bit
perplexing in light of findings in vaccinated and infected non-
human primates where correlations between ADCC and viral load
have been observed [37,78,79]. However, the ADCC assay
employed offers low sensitivity and is a semi-quantitative assay
[80]. Secondly, a number of epitopes within both gp120 and gp41
have been recognized to mediate ADCC activity [35,81,82]. In
this study, only recombinant gp120 (and not gp41) was used to
assess ADCC responses. Most importantly, because the subtype A
gp120 did not permit the measurement of ADCC, the assay was
performed using a subtype B gp120, which may entirely explain
the lack of correlations with ADCC observed using subtype A
infected patient sera. Finally, in vivo, ADCC involves components
of both the innate and humoral immune systems and here we
examined only the antibody function, and not cellular effector
function, in these subtype A infected patients. We have previously
shown alterations to the NK cell compartment, the primary cells
that mediate ADCC, in HIV-1 infected Ugandans [83], however,
further work will be required to assess the influence of the breadth
and magnitude of ADCC on disease progression in different HIV-
1 subtypes.
Here we have demonstrated for the first time, what appears to
be an inverse relationship between peripheral blood B cell
numbers and the magnitude and frequency of functional NAbs
in subtype A infected subjects. We further demonstrate preferen-
tial neutralization of subtype A and CRF02_AG viruses by
subtype A sera from Uganda. Studies of this nature may yield
important insights for defining the relationship between functional
antibodies, B cell populations and other prognostic markers in
regions where multiple non-B HIV-1 subtypes are prevalent.
Future studies in well-controlled acute infection cohorts will
provide information that will augment these findings and better
inform HIV vaccine development.
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